This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia). Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing. In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
Timeframe: 24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
Timeframe: 24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
Timeframe: 24 months